<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466957</url>
  </required_header>
  <id_info>
    <org_study_id>ERID-KESOPKR/63</org_study_id>
    <nct_id>NCT03466957</nct_id>
  </id_info>
  <brief_title>Individual Approach in Gynecological Cancer Brachytherapy</brief_title>
  <official_title>Development and Assessment of Individual 3D Printed Applicators in MRI Guided Gynecological Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRI guided adaptive brachytherapy (BT) represents the gold standard in the treatment of
      gynecological cancers. Commercially available standard MRI compatible applicators for BT of
      gynecological cancers don't always allow for optimal target volume coverage.
      Three-dimensional (3D) printed technology enables versatile possibilities of improvement of
      standard applicators and development of novel applicators with better coverage of the target
      volume. The purpose of this study is to implement and assess 3D printing technology as an
      instrument for designing and manufacturing applicators for individualized BT of gynecological
      cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with locoregionally gynecological cancers will be included in this
      single-institution, non-randomized, one-arm study. All patients will receive 45-50 Gy
      external beam radiotherapy (EBRT) with intensity-modulated radiotherapy/volumetric-modulated
      arc therapy (IMRT/VMAT) technique, 1.8-2 Gy/fraction +/- concurrent cisplatin based
      chemotherapy. First BT with commercially available standard applicators (tandem with ring +/-
      parallel needles or vaginal cylinder) will be carried out. MRI with applicator in situ will
      be performed, high-risk clinical target volume (CTV-HR) and organs at risk (OAR) will be
      delineated and treatment planning will be conducted. In the case of large gynecological
      cancer and suboptimal target coverage at BT (V100 ≤ 90%, D98 ≤ 80%, D90 ≤ 100%, D100 ≤ 60%) a
      preplan will be performed as the basis for the 3D applicator modelling. The next BT
      application will be performed with an individually designed 3D printed applicator.
      Dose-volume characteristics of the following treatment plans will be compared: the preplan,
      the plan with standard and the plan with individual 3D printed applicator.

      The primary objective of the study is to determine the improvement of dose-volume parameters
      with the use of 3D printed individual applicators in advanced gynecological cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target volume CTV-HR</measure>
    <time_frame>at two hours after the end of brachytherapy procedure</time_frame>
    <description>V100 (%), D90 (%), D98 (%), D100 (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>organs at risk</measure>
    <time_frame>at two hours after the end of brachytherapy procedure</time_frame>
    <description>D2cc (Gy), D0.1cc (Gy), Dmax (Gy)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>3D printed applicator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>individually designed applicator for BT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3D printed applicator</intervention_name>
    <description>add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application</description>
    <arm_group_label>3D printed applicator</arm_group_label>
    <other_name>individual applicator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with locally advanced gynecological cancer (cervical, uterine, vaginal,
             vulvar cancer) eligible for treatment with brachytherapy

          -  squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma, histologically
             proven

          -  patients fit for regional or general anesthesia

          -  signed written informed consent

        Exclusion Criteria:

          -  regional or general anesthesia contraindications

          -  contraindications for MRI
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Barbara Zobec Logar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brachytherapy Department, Institute of Oncology Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Barbara Zobec Logar, MD</last_name>
    <phone>0038615879204</phone>
    <email>hlogar@onko-i.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violeta Kaluza</last_name>
      <phone>0038115879122</phone>
      <email>vkaluza@onko-i.si</email>
    </contact>
    <investigator>
      <last_name>Helena Barbara Zobec Logar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Šegedin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Hudej, physicist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manja Šešek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>image guided brachytherapy</keyword>
  <keyword>3D print</keyword>
  <keyword>gynecological cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

